Grupo para la caracterización molecular de las neoplasias hematológicas
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (24)
2024
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
Leukemia and Lymphoma, Vol. 65, Núm. 3, pp. 323-332
-
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Blood, Vol. 143, Núm. 17, pp. 1713-1725
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
The Lancet, Vol. 401, Núm. 10373, pp. 269-280
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 31, Núm. 9, pp. 1863-1866
-
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843
-
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine, Vol. 28, Núm. 2, pp. 325-332
2021
-
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336
2016
-
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
Cancer, Vol. 122, Núm. 14, pp. 2178-2185
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial
Haematologica, Vol. 100, Núm. 8, pp. 1096-1102
-
Revised international staging system for multiple myeloma: A report from international myeloma working group
Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869
-
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement
Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664
2014
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542
2013
-
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm
British Journal of Haematology, Vol. 161, Núm. 5, pp. 667-676
-
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Leukemia, Vol. 27, Núm. 4, pp. 780-791